Mason, you certainly are to be congratulated for your "many hours of research" which leads you to the conclusion that there are multiple clinical and commercial risks for CF33. I'm sure those "many hours" spent online, reading the content that was provided to you directly by a poster on these forums, outweighs the years of clinical research by Professor Fong and his extended team.
Now, whilst you point out that the IV administration of CF33 may be less effective than intratumoral or intraperitoneal administration, something the authors of the document also note when they write "IP treatment on D0 and D2 significantly improved survival compared to PBS or IV treatment", you appear to have completely disregarded the following evidence that demonstrates CF33's effectiveness at reducing tumour burden.
See below:
There is very clearly a positive outcome on tumor burden for IV administration on day 2 treatment.
As others have pointed out, pancreatic cancer and indeed triple negative breast cancer, are some of the deadliest and most aggressive forms of cancer. For CF33, the effectiveness of IV administration will of course be dose dependent given the rate at which the cancer spreads. The Vaxinia trial, approved by the FDA, will further inform us of the effectiveness of IV administration in humans. That's the data we want.
Why would they approve a trial if there wasn't the data to support it?
So if CF33 is effective at killing cancer - and we know it is - the route of administration becomes a bit of a moot point. After all, it has demonstrated some efficacy in all three routes of administration in the literature.
IMU Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)